ARA-290 research: quick summary
ARA-290, catalogued as cibinetide, is a synthetic eleven-residue peptide reproducing a surface region of the erythropoietin helix-B domain, supplied by Red Leaf Research Labs as a 10 mg lyophilized research material. Published laboratory work describes it in relation to the EPOR–βcR heteromer, also written as the innate repair receptor. It is not an authorized medicine in Canada, is for laboratory research use only, is not for human or veterinary use, and carries no dosing or protocol information.
ARA-290 Canada: ARA-290 10mg Research Product
ARA-290 is stocked in a 10 mg lyophilized fill, sold to qualified laboratory purchasers in Canada. Described below are the material, its lot paperwork and dispatch terms, and nothing else.
People reach this page through buy ARA-290 Canada, ARA-290 peptide Canada and cibinetide Canada. Those queries are logged as behaviour, not endorsed. A personal-health motive belongs with a clinician.
Red Leaf Research Labs supplies ARA-290 as a research chemical. No claim of outcome is made, no dosing instruction is issued, and it is not offered for administration to any person or animal.
ARA-290 10mg Research Format and Options
| Attribute | Detail |
|---|
| Research format | One vial, 10 mg ARA-290 (cibinetide), lyophilized |
| Physical state | Dried cake, sealed glass vial |
| Analytical documentation | Independent lot report, methods named |
| Fulfilment | Canadian dispatch to research addresses |
| Intended use | Laboratory research only; not for human or veterinary use |
Vial size reflects how the material is packed for sale, not any view about experimental scale.
ARA-290 Research Specifications
- Compound name: Cibinetide
- Alternative name(s): ARA-290, pyroglutamate helix B surface peptide, pHBSP
- Research shorthand: ARA-290
- Peptide/compound class: Synthetic 11-mer, non-erythropoietic EPO-derived peptide
- Receptor or pathway interest: EPOR–βcR (CD131) heteromer, termed the innate repair receptor in the literature
- Structural origin: Glp-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser, a solvent-exposed face of erythropoietin helix B
- CAS: 1208243-50-8
- Molecular formula: C51H84N16O21
- Molecular weight: approximately 1257.3 g/mol
- Physical format: Freeze-dried solid
- Available research quantity: 10 mg per vial
- Intended use: Laboratory research use only
- Fulfilment: Dispatch inside Canada
What Is ARA-290?
ARA-290 is a linear eleven-residue peptide reproducing part of the outer face of helix B in erythropoietin, a region exposed to solvent in the folded protein rather than buried in the interface used to engage the homodimeric receptor. The N-terminal residue is pyroglutamate, hence the alternative name pyroglutamate helix B surface peptide.
ARA-290 is most often confused with erythropoietin itself and with erythropoiesis-stimulating agents such as epoetin alfa and darbepoetin alfa. Those are recombinant glycoproteins regulated as biologic medicines. ARA-290 is a chemically synthesised eleven-mer with no carbohydrate and no folded tertiary structure. Sharing a sequence fragment with a protein does not make a peptide a version of it.
ARA-290 and Innate Repair Receptor Research
Published work on ARA-290 centres on a heteromer of the erythropoietin receptor subunit and the common beta subunit CD131, called the innate repair receptor there. The rationale there is that the helix-B surface region is not the face erythropoietin uses to bind the homodimer associated with red cell production, so a peptide reproducing it is studied as a probe for the heteromer instead. Reported experiments include binding assays, work in cultured cells expressing the relevant subunits, and studies in rodent tissue.
All of that describes measurements in binding assays, cultured cells and animal tissue. Receptor or pathway activity in a model does not establish that any effect occurs in a person.
Why Buy ARA-290 10mg in Canada from a Domestic Research Supplier?
The routine argument is time and temperature. A parcel routed only within Canada avoids the customs hold, the one segment of an international route with no thermal record.
The argument with more force here is category. This peptide shares a sequence region with a regulated biologic, and buyers want written confirmation that a synthetic eleven-mer shipped.
Both are logistics and contract points, not statements about the lot or its certificate.
How This ARA-290 Canada Page Improves on Typical Competitor Listings
Many listings reuse a template and change the name. This page differs in five ways.
- The copy describes ARA-290 structurally, naming its eleven-residue sequence and pyroglutamate N-terminus, not generic peptide language.
- The analytical basis is stated, not asserted: a report tied to the lot in stock, naming the methods used.
- No claim of outcome, benefit or safety is made here, nor implied by omission.
- The regulatory position is explicit: cibinetide has been under registered clinical investigation; this vial is a different category of product.
- Structural relationships are named, so a purchaser can see what ARA-290 is not.
How to Evaluate an ARA-290 Certificate of Analysis
The N-terminus dictates how this peptide is confirmed. Residue one is pyroglutamate, which blocks Edman sequencing, so identity rests on mass and fragmentation instead.
- Compound identity: cibinetide or ARA-290, against CAS 1208243-50-8, with the pyroglutamate terminus stated.
- Lot reference: the lot number on the certificate matches the number on the vial.
- Analysis date: when the analysis ran, relative to the date of synthesis.
- Test methods: the chromatography named, and a mass method resolving uncyclised glutamine from the pyroglutamate form.
- Measured quantity: the amount the document covers, set against the 10 mg on the label.
- Purity result: the value returned, quoted with the method behind it.
- Laboratory verification: the testing laboratory identified, and its independence from the seller.
A mass near 1257 fits the cyclised eleven-mer; a species seventeen daltons heavier fits an N-terminal glutamine that never closed the ring.
ARA-290 10mg Lyophilized Research Format
This vial holds a freeze-dried solid. The solution is frozen, pressure is dropped, and the ice leaves as vapour without melting, so the peptide reaches a dry state without being heated.
Sequence composition sets what to watch afterwards. An asparagine and a serine-serine pair near the C-terminus are the residues discussed in connection with deamidation and succinimide intermediates, both of which proceed in water rather than in a dry cake. Moisture, temperature cycling, light and freeze-thaw apply as well. Handling conditions are fixed by the receiving institution, not by this listing.
How to Buy ARA-290 in Canada for Qualified Research
- Confirm eligibility. Determine that your organization may lawfully take delivery of research chemicals.
- Review documentation. Read the lot report, checking it describes a synthetic peptide, not a protein preparation.
- Select quantity. Set the number of 10 mg vials from the written plan.
- Check shipping route. Confirm the domestic route and transit window against receiving hours.
- Record receipt. Enter lot number, arrival date and vial condition at goods-in.
These are procurement and record-keeping steps alone, constituting no dosing or study-design advice.
ARA-290 Availability in Canada: Research vs. Consumer Searches
Cibinetide has been examined in registered clinical trials, so the name appears in trial registries. That is not market authorisation. ARA-290 is not an authorized medicine in Canada and has not been assessed by Health Canada for use in a person.
A finished pharmaceutical product is a specified formulation made to pharmaceutical standards, with approved labelling, dispensed under prescription. The vial here is none of those, and is not a version of any product sharing the name.
A personal-health interest in cibinetide belongs with a licensed clinician, not with this listing.
ARA-290 10mg Canada Procurement Checklist
| Check | What to confirm |
|---|
| Purpose | Laboratory research within an organization eligible to receive it |
| Identity | Cibinetide or ARA-290, CAS 1208243-50-8, pyroglutamate terminus noted |
| Distinctness | A synthetic 11-mer, not erythropoietin or a recombinant ESA |
| Quantity | Vial count fixed by the written plan |
| Documentation | Lot report whose mass method confirms the cyclised N-terminus |
| Verification | Whether an independent laboratory repeats the identity work |
| Handling | Dry storage arranged, deamidation being a solution-phase process |
Explore ARA-290 Research Information
Background reading: the ARA-290 research guide, how peptides work, and what third-party testing tells a purchaser.
ARA-290 research FAQ
Does Red Leaf Research Labs provide dosing information?
No. No dosing information, reconstitution volume, concentration, route or protocol is provided for this or any product.
Working out concentration for this vial? Our peptide reconstitution calculator converts vial size and bacteriostatic water volume into mg per mL and U-100 syringe units.
Is ARA-290 the same thing as erythropoietin?
No. ARA-290 is an eleven-residue synthetic peptide reproducing a surface region of the erythropoietin helix-B domain; erythropoietin is a recombinant glycoprotein.
Why is cibinetide also called pHBSP?
Because it corresponds to the helix-B surface sequence and carries an N-terminal pyroglutamate. Both names appear in the literature for the same compound.
What documentation comes with the 10mg vial?
An external laboratory report exists for the lot currently held, naming the lot and the analytical techniques used.
Can Red Leaf Research Labs advise on experimental design?
No. That is the buyer’s remit: models, controls, endpoints and everything downstream of them.
Research use only. ARA-290 (cibinetide) 10 mg is supplied strictly for laboratory research. It is not an authorized medicine in Canada, is not for human or veterinary use, and carries no dosing or protocol information. A personal-health question about cibinetide belongs with a licensed clinician.
Owned and operated by a cf veteran 
